Pabst Patent Group LLP | David Shore
This links to the home page
Attorneys
David  A. Shore

EDUCATION

D. Phil., Biochemistry
University of Oxford

B.Sc., Medical Microbiology
University College, London
David A. Shore, D. Phil.
Senior Scientific Advisor
CONTACT INFORMATION
Tel: 404.879.2345
Fax: 404.879.2160
v-card icon V-Card

David A. Shore, D. Phil., serves as a Scientific Advisor in the areas of biotechnology and pharmaceuticals.

Dr. Shore assists with drafting patent applications, prosecuting U.S. patent applications and corresponding with foreign associates to guide the prosecution of foreign applications.

Dr. Shore has more than a decade of research experience in a diverse range of technological areas and is especially accomplished in the field of protein biochemistry.  Dr. Shore studied infectious diseases as an undergraduate and his Ph.D. research focused on characterization of glycoproteins at the surface of immune cells.  As a post-doctoral fellow at The Scripps Research Institute Dr. Shore determined the X-ray structures of proteins that govern activation of cellular immune responses.  Following completion of his post doctoral studies Dr. Shore served as a research fellow with the Influenza Division of the Centers for Disease Control and Prevention (CDC), where he assisted the development of novel influenza vaccines.

Dr. Shore is named as a co-inventor on multiple patent applications and has co-authored numerous journal articles, including "Structural characterization of a protective epitope spanning A(H1N1)pdm09 influenza virus neuraminidase monomers" (Nature Communications, 2015), "Structural stability of influenza A(H1N1)pdm09 virus hemagglutinins" (Journal of Virology, 2014), "Structural and antigenic variation among diverse clade 2 H5N1 viruses" (PLoS One, 2013), "T cell receptors are structures capable of initiating signaling in the absence of large conformational rearrangements”, (Journal of Biological Chemistry, 2012); “The crystal structure of CD8 in complex with YTS156.7.7 Fab and interaction with other CD8 antibodies define the binding mode of CD8 alpha-beta to MHC class I” (Journal of Molecular Biology, 2008), "Crystal structure of the TCR co-receptor CD8alphaalpha in complex with monoclonal antibody YTS 105.18 Fab fragment at 2.88 A resolution" (Journal of Molecular Biology, 2006), and “Glycosylation and the function of the T cell co-receptor CD8” , Advances in Experimental and Medicine and Biology (2005).